Skip to main content
. 2017 Oct 12;12(10):e0186449. doi: 10.1371/journal.pone.0186449

Fig 3. The distribution of MACCEs probabilities of 5 treatments being ranked at possible positions.

Fig 3

MACCEs, main adverse cardiac and cerebrovascular events; DAPT, dual-antiplatelet therapy; Riva15 + P2Y12, rivaroxaban 15 mg/d plus P2Y12 inhibitor; Riva2.5 + P2Y12, rivaroxaban 2.5 mg bid plus P2Y12 inhibitor; TT, triple-antiplatelet therapy; VKA, vitamin K antagonist; SAPT, single antiplatelet therapy.